237 related articles for article (PubMed ID: 36680243)
21. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
[TBL] [Abstract][Full Text] [Related]
22. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
[TBL] [Abstract][Full Text] [Related]
23. Influenza H3 hemagglutinin vaccine with scrambled immunodominant epitopes elicits antibodies directed toward immunosubdominant head epitopes.
Chiba S; Kong H; Neumann G; Kawaoka Y
mBio; 2023 Aug; 14(4):e0062223. PubMed ID: 37466314
[TBL] [Abstract][Full Text] [Related]
24. Inactivated influenza virus vaccines expressing COBRA hemagglutinin elicited broadly reactive, long-lived protective antibodies.
Shi H; Zhang X; Ge P; Meliopoulos V; Freiden P; Livingston B; Schultz-Cherry S; Ross TM
Hum Vaccin Immunother; 2024 Dec; 20(1):2356269. PubMed ID: 38826029
[TBL] [Abstract][Full Text] [Related]
25. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
J Virol; 2017 May; 91(9):. PubMed ID: 28179535
[TBL] [Abstract][Full Text] [Related]
26. Differential Recognition of Computationally Optimized H3 Hemagglutinin Influenza Vaccine Candidates by Human Antibodies.
Abbadi N; Nagashima K; Pena-Briseno A; Ross TM; Mousa JJ
J Virol; 2022 Aug; 96(16):e0089622. PubMed ID: 35916534
[TBL] [Abstract][Full Text] [Related]
27. Pandemic influenza 1918 H1N1 and 1968 H3N2 DNA vaccines induce cross-reactive immunity in ferrets against infection with viruses drifted for decades.
Bragstad K; Martel CJ; Thomsen JS; Jensen KL; Nielsen LP; Aasted B; Fomsgaard A
Influenza Other Respir Viruses; 2011 Jan; 5(1):13-23. PubMed ID: 21138536
[TBL] [Abstract][Full Text] [Related]
28. Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine.
Tete SM; Jul-Larsen Å; Rostami S; Lunde THF; Søland H; Krammer F; Cox RJ
Vaccine; 2018 Apr; 36(16):2213-2219. PubMed ID: 29548607
[TBL] [Abstract][Full Text] [Related]
29. A Computationally Optimized Broadly Reactive Antigen Subtype-Specific Influenza Vaccine Strategy Elicits Unique Potent Broadly Neutralizing Antibodies against Hemagglutinin.
Sautto GA; Kirchenbaum GA; Abreu RB; Ecker JW; Pierce SR; Kleanthous H; Ross TM
J Immunol; 2020 Jan; 204(2):375-385. PubMed ID: 31811019
[TBL] [Abstract][Full Text] [Related]
30. Novel influenza vaccine M2SR protects against drifted H1N1 and H3N2 influenza virus challenge in ferrets with pre-existing immunity.
Hatta Y; Boltz D; Sarawar S; Kawaoka Y; Neumann G; Bilsel P
Vaccine; 2018 Aug; 36(33):5097-5103. PubMed ID: 30007825
[TBL] [Abstract][Full Text] [Related]
31. Broadly Protective CD8
Zhang H; Zheng H; Guo P; Hu L; Wang Z; Wang J; Ju Y; Meng S
J Virol; 2021 May; 95(12):. PubMed ID: 33827939
[TBL] [Abstract][Full Text] [Related]
32. Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques.
Florek KR; Weinfurter JT; Jegaskanda S; Brewoo JN; Powell TD; Young GR; Das SC; Hatta M; Broman KW; Hungnes O; Dudman SG; Kawaoka Y; Kent SJ; Stinchcomb DT; Osorio JE; Friedrich TC
J Virol; 2014 Nov; 88(22):13418-28. PubMed ID: 25210172
[TBL] [Abstract][Full Text] [Related]
33. Novel H7N9 influenza immunogen design enhances mobilization of seasonal influenza T cell memory in H3N2 pre-immune mice.
Moise L; Meyers LM; Jang H; Grizotte-Lake M; Boyle CM; McGonnigal B; Ge P; Ross TM; De Groot AS
Hum Vaccin Immunother; 2022 Nov; 18(4):2082191. PubMed ID: 35704783
[TBL] [Abstract][Full Text] [Related]
34. A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets.
Giles BM; Ross TM
Vaccine; 2011 Apr; 29(16):3043-54. PubMed ID: 21320540
[TBL] [Abstract][Full Text] [Related]
35. A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection.
Giles BM; Crevar CJ; Carter DM; Bissel SJ; Schultz-Cherry S; Wiley CA; Ross TM
J Infect Dis; 2012 May; 205(10):1562-70. PubMed ID: 22448011
[TBL] [Abstract][Full Text] [Related]
36. Mosaic H5 Hemagglutinin Provides Broad Humoral and Cellular Immune Responses against Influenza Viruses.
Kamlangdee A; Kingstad-Bakke B; Osorio JE
J Virol; 2016 Aug; 90(15):6771-6783. PubMed ID: 27194759
[TBL] [Abstract][Full Text] [Related]
37. COBRA HA and NA vaccination elicits long-live protective immune responses against pre-pandemic H2, H5, and H7 influenza virus subtypes.
Ge P; Ross TM
Virology; 2024 Jun; 597():110119. PubMed ID: 38850895
[TBL] [Abstract][Full Text] [Related]
38. Greater Breadth of Vaccine-Induced Immunity in Females than Males Is Mediated by Increased Antibody Diversity in Germinal Center B Cells.
Ursin RL; Dhakal S; Liu H; Jayaraman S; Park HS; Powell HR; Sherer ML; Littlefield KE; Fink AL; Ma Z; Mueller AL; Chen AP; Seddu K; Woldetsadik YA; Gearhart PJ; Larman HB; Maul RW; Pekosz A; Klein SL
mBio; 2022 Aug; 13(4):e0183922. PubMed ID: 35856618
[TBL] [Abstract][Full Text] [Related]
39. A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.
Wu CY; Yeh YC; Chan JT; Yang YC; Yang JR; Liu MT; Wu HS; Hsiao PW
PLoS One; 2012; 7(8):e42363. PubMed ID: 22879951
[TBL] [Abstract][Full Text] [Related]
40. A computationally designed H5 antigen shows immunological breadth of coverage and protects against drifting avian strains.
Ross TM; DiNapoli J; Giel-Moloney M; Bloom CE; Bertran K; Balzli C; Strugnell T; Sá E Silva M; Mebatsion T; Bublot M; Swayne DE; Kleanthous H
Vaccine; 2019 Apr; 37(17):2369-2376. PubMed ID: 30905528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
